Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model
November 2022
in “
The Journal of Urology
”
Studysummary This study suggests that adopting the Mark Cuban Cost Plus Drug Company model for purchasing urological medications could have saved Medicare about $1.29 billion in 2020.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on auajournals.org →